RSS-Feed abonnieren
PDF herunterladen
DOI: 10.1055/s-0042-1749399
Systemic Immune-Inflammation Index Predicts Outcomes in Platinum-Resistant Relapsed Ovarian Cancer
Authors
Funding The study was supported by JIPMER. No grant number is applicable.
Abstract
We explored the prognostic impact of simple indices that reflect the immunological milieu (neutrophils to lymphocyte ratio [NLR] and systemic immune-inflammation [SII]) in 49 platinum-resistant relapsed ovarian cancer patients. The median progression-free survival (PFS) and overall survival (OS) were 4 and 8 months, respectively. Patients with a lower NLR (≤2.89) had a better PFS (5 vs. 2 months [p = 0.02]) and OS (9 vs. 5 months [p = 0.20]). Factors associated with a worse PFS were NLR > 2.8 (hazard ratio [HR] =2.32, p = 0.02) and SII > 639 (HR =3.70, p = 0.002). SII > 639 independently predicted PFS (HR =4.13, p = 0.03). Future studies should study the validity of inflammatory markers and could consider incorporating it as a biomarker in clinical trials.
Keywords
platinum-resistant ovarian cancer - treatment - outcomes - systemic immune-inflammation index - neutrophil to lymphocyte ratioEthical Approval
The study was approved by JIPMER IEC (EC Approval No: JIP/IEC/2019/558).
Publikationsverlauf
Artikel online veröffentlicht:
28. Juli 2022
© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Ferlay J, Soerjomataram I, Dikshit R. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136 (05) E359-E386
- 2 Davis A, Tinker AV, Friedlander M. “Platinum resistant” ovarian cancer: what is it, who to treat and how to measure benefit?. Gynecol Oncol 2014; 133 (03) 624-631
- 3 Farolfi A, Scarpi E, Greco F. et al. Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study. Sci Rep 2020; 10 (01) 18190
- 4 Nie D, Gong H, Mao X, Li Z. Systemic immune-inflammation index predicts prognosis in patients with epithelial ovarian cancer: a retrospective study. Gynecol Oncol 2019; 152 (02) 259-264
- 5 Kossaï M, Leary A, Scoazec J-Y, Genestie C. Ovarian cancer: a heterogeneous disease. Pathobiology 2018; 85 (1-2): 41-49
- 6 Zhao H, Wu L, Yan G. et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther 2021; 6 (01) 263
- 7 Goenka L, Nakka T, Dubashi B. et al. A simple, novel prognostic score in platinum sensitive relapsed ovarian cancer. Am J Clin Oncol 2021; 44 (08) 434-441
- 8 Powell DR, Huttenlocher A. Neutrophils in the tumor microenvironment. Trends Immunol 2016; 37 (01) 41-52
- 9 Hwang W-T, Adams SF, Tahirovic E, Hagemann IS, Coukos G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol 2012; 124 (02) 192-198
- 10 Han LY, Fletcher MS, Urbauer DL. et al. HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res 2008; 14 (11) 3372-3379
- 11 Lee CK, Asher R, Friedlander M. et al. Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy. Eur J Cancer 2019; 117: 99-106
- 12 Previs RA, Bevis KS, Huh W. et al. A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy. Gynecol Oncol 2014; 132 (03) 531-536